Period in Biological Technology
Navigation Links
Period in Biological Technology
SCOLR Pharma, Inc. Reports Second Quarter 2009 Financial Results
... June 30, 2009, compared to $279,571 for the same period in 2008. This decrease is primarily due to lower ... June 30, 2009, compared to $545,126 for the same period in 2008. This decrease is primarily due to lower ... June 30, 2009, compared to $191,047 for the same period in 2008 and decreased 66%, or $282,688 to ...Catalyst Pharmaceutical Partners Reports Second Quarter 2009 Financial Results
... or $0.19 per basic and diluted share for the same period in 2008. Second quarter 2009 results included ... of $64,532, compared to $123,208 in the same period in 2008. For the six months ended June 30, 2009, ... loss per basic and diluted share, for the same period in 2008. Results for the first six months of 2009 ...Synthetech Reports First Quarter Fiscal 2010 Results
... to operating income of $314,000 for the same period last year. Net income for the current quarter ... incentives compared to $41,000 in the comparable period of fiscal 2009. As a cautionary measure, in May ... revenue will continue to be volatile from period to period. Variability in Synthetech's level of ...Microbix Sales Grow 22% For Nine Months
... of $945,111 or three cents a share in the same period in fiscal 2008. The company's negative cash ... to negative cash flow $ 1,079,492 in the same period in 2008. A lower loss for the third quarter ... and stable revenues compared to the same period in 2008. Losses associated with research and ...GenVec Reports Second Quarter 2009 Financial Results
... under both the FMD and malaria programs in each period are due mainly to the scope of work performed in ... under the malaria program for the six-month period is the limited work conducted prior to the ... revenue associated with our HIV program in each period is due mainly to increased research and process ...InterMune Reports Second Quarter 2009 Financial Results and Business Highlights
... of 2009, compared with $7.1 million in the same period a year earlier, an increase of approximately 20 ... months ended June 30, 2009. The net loss for the period was $78.7 million, or $1.83 per share, compared ... with total revenue of $17.4 million in the same period of 2008, a decrease of 15 percent. Actimmune ...SEQUENOM Reports Second Quarter 2009 Financial Results and Highlights
... quarter of 2008. The decrease from the comparable period last year was primarily due to softness in ... of 2009, compared with $6.4 million for the same period in the prior year. Research and development ... net loss per share was 61,137,755 for this period versus 47,146,856 for the second quarter of 2008. ...Telik Announces Second Quarter 2009 Financial Results
... million, or $0.26 per share, for the comparable period in 2008. For the quarter ended June 30, ... the second quarter of 2009 compared with the same period in 2008, primarily due to lower headcount as a ... first six months of 2009 compared with the same period in 2008 was primarily due to lower headcount, ...... of 2009 was based on BSC's net sales for the period January 1, 2009 to March 31, 2009 of $252 ... gross royalty rate earned in the three month period ended June 30, 2009 on BSC's net sales was 6.6% ... years. We may, at our sole discretion, during a period of two years, advance up to an additional $1 ...
... million, compared to $28.7 million for the same period in 2008. The decrease is mainly a result of a 54% ... quarter ended June 30, 2009, compared to the same period in 2008. Total operating expenses included ... of $59.3 million ($5.18 per share) for the same period in 2008. The reduction in net loss per share is ...
PDI Reports 2009 Second Quarter Financial Results
... engagements, coming during what has been a slow period in the industry, and given the strategic shift in ... million, compared to $30.4 million in the same period last year. Revenue in the Sales Services segment ... million, compared to $23.4 million in the same period of 2008. While Sales Services has gained revenue ...Amicus Therapeutics Announces Second Quarter 2009 Financial Results
... million as compared to $9.3 million for the same period in 2008. On a non-GAAP basis, the net loss for ... million as compared to $7.4 million in the same period in 2008. Amicus recorded revenue during ... period from ...Cadence Pharmaceuticals Reports Second Quarter 2009 Financial Results
... $15.6 million, or $0.41 per share, for the same period in 2008. For the six months ended June 30, 2009, ... $29.3 million, or $0.83 per share, for the same period in 2008. The per share amount for the three and ... the $15.6 million reported for the comparable period in 2008. Operating expenses for the six months ...Shire plc: Core Portfolio of Products Delivers 20% Sales Growth
... (1) Figures compare Q2 2009 results with the same period in 2008. (2) Sales growth at constant ... US prescription demand in Q2 2009 over the same period in 2008, as a result of increased US ADHD average ... retail pharmacies in Q2 2009 compared to the same period in 2008. These factors more than offset the ...... to common shares of $22.6 million) for the same period in 2008. Total operating expenses for the ... 2009, compared with $23.4 million for the same period in 2008. Total operating expenses for the six ... 2009, compared with $15.5 million for the same period in 2008. General and administrative ...
... will announce its financial results for this period in a press release to be issued prior to the ... for replay at http://www.keryx.com , for a period of 15 days after the call. The press release announcing our financial results for this period will be posted on the Company's website, ...
Hoya Announces First Quarter Financial Results for FY2010
... 27.0% decrease from 130.1 billion yen in the same period last year, and operating income was 9.2 billion ... 57.5% decrease from 21.8 billion yen in the same period last year, mainly due to order decrease and the ... were 8.90 yen compared with 48.97 yen in the same period last year. "Net sales decreased compared ...ERT Reports Second Quarter 2009 Results
... results for the second quarter and six-month period ended June 30, 2009. Unless otherwise noted, all ... numbers refer to changes from the same period a year ago. Highlights of the second ... 2,353 Cash and cash equivalents, beginning of period 38,082 66,376 ...Endo Pharmaceuticals Reports Strong Second Quarter 2009 Financial Results
... million, compared with $72.7 million in the same period in 2008. Diluted earnings per share for the three ... 2009, were $0.73, compared with $0.59 in the same period in 2008. Total revenues for the six months ... 2009, were $1.41, compared with $1.09 in the same period in 2008. ($in thousands, ...Mylan Reports Adjusted Diluted EPS of $0.32 for the Quarter Ended June 30, 2009
... volumes and new product launches, while prior period revenues in the U.K. were negatively impacted by ... respectively. The remainder in each period relates to integration and other ... of South Africa. The remainder in each period relates to integration and other ...Oncolytics Biotech(R) Inc. Announces 2009 Second Quarter Results
... Six Month period period Period ... Net loss and comprehensive loss for the period 4,334,757 5,254,530 ...Sangamo BioSciences Reports Second Quarter 2009 Financial Results
... of $7.4 million, or $0.18 per share, for the same period in 2008. As of June 30, 2009, the company had ... million, compared to $2.8 million for the same period in 2008. Second quarter 2009 revenues were from ... of 2009, compared to $8.3 million for the same period in 2008. The decrease in research and ...Neurocrine Biosciences Reports Second Quarter 2009 Results
... $21.0 million, or $0.55 per share, for the same period in 2008. For the six months ended June 30, 2009, ... $42.0 million, or $1.10 per share, for the same period last year. Revenues for the second quarter ... million, compared with $2.5 million for the same period in 2008. The decrease in revenues is primarily ...Sanofi-aventis Announces Second Quarter 2009 Results
... more than tripling relative to the comparable period of 2008 (to euro 284 million). On a constant ... Zentiva and other companies acquired during the period remeasured at fair value. An amortization ... with euro 3,932 million for the comparable period of 2008. Working capital needs increased ...Cynosure Reports Second Quarter 2009 Financial Results
... million, compared with $39.2 million in the same period of 2008 and $14.8 million in the first quarter of ... total revenues, compared with 67.1% for the same period of 2008 and 60.9% in the first quarter of 2009. ... in the second quarter from 30% in the same period of 2008 and 43% in the first quarter of 2009. We ...BioMS Medical announces second quarter 2009 results
... ($7.1) million or ($0.08) per share for the same period in 2008. Revenue earned from the collaboration ... 2009 compared with $9.3 million or 82% for this period in 2008. Total consolidated expenses for the six ... 2009 compared with $22.5 million or 67% for this period in 2008. As at June 30, 2009, cash and cash ...Vasogen Announces Second Quarter 2009 Results
... million, or $0.33 per common share for the same period in 2008. The $1.4 million loss for the three ... million, or $0.57 per common share for the same period in 2008. The loss for the three and six months ... our Management's Discussion and Analysis for the period ended May 31, 2009. The forward-looking ...Santaris Pharma - Interim Report for the Period 1 January to 30 June 2009
... Pharma has approved the Interim Report for the period 1 January to 30 June 2009. - The loss ... to 23,1m DKK (3,1m EUR) for the same period last year. Following the refocusing of the ... DKK (2,8m EUR). The year to date saving for the period 1 January to 30 June 2009 compared to the same ...Johnson & Johnson Completes Initial Tender Offer for Cougar Biotechnology
... JNJ ) today announced that the initial offering period of its tender offer for all outstanding shares of ... properly withdrawn during the initial offering period have been accepted for payment. The ... Kite Merger Sub, Inc. a subsequent offering period of its tender offer to acquire all remaining ...... growth potential for prescription drugs over the period 2006-2015. Oncologics/Cancer Drugs market is ... and Rest of World. Analytics for the period 2006-2015 provide a comprehensive understanding ... Additionally, historic review is provided for the period 2001 to 2005. Global players profiled in the ...
Trubion Pharmaceuticals Announces Extension of Research Period Under Its Wyeth Collaboration
... agreement with Trubion to extend the research period for an additional one-year period through Dec. 22, 2010. Under the terms of the research period extension, Wyeth's obligations to Trubion include ...Helix BioPharma Announces Q3 2009 Financial Results and Provides Product Development Update
... periods ended April 30, 2009 compared to the same period in the previous year Loss for the period The Company recorded a loss of $4,134,000 and ... Revenues Total revenues for the three month period ended April 30, 2009 totaled $924,000 (2008 - ...Repligen Reports Fourth Quarter and Fiscal Year 2009 Financial Results
... $4,594,000 compared to $3,301,000 for the same period in fiscal year 2008, an increase of 39%. ... $7,809,000, compared to $7,165,000 for the same period in fiscal year 2008. Net loss for the fourth ... $3,198,000 or $0.10 per diluted share in the same period in fiscal year 2008. Corporate Update ...... and first-time profitability for the three-month period ended February 28, 2009. Neptune and Acasti ... compares the results of the three and nine-month period ended February 28, 2009 to the unaudited three and nine-month period of the previous fiscal year ended February 29, ...
Simcere Pharmaceutical Group Reports Unaudited First Quarter 2009 Results
... RMB394.6 million for the corresponding period in 2008, representing 12.1% year-over-year ... from RMB99.2 million for the corresponding period in 2008. -- Net income attributable to ... compared to 83.2% for the corresponding period in 2008. Mr. Jinsheng Ren, Chairman and ...China Biologic Products Announces Strong First Quarter 2009 Results
... instead of at the regular 25% rate, for a period of 3 years commencing January 1, 2008. -- ... quarter of 2009, as compared to 58.1% in same period a year ago. Sales of human albumin products ... quarter of 2008. Gross margin was 70.6% for the period ended March 31, 2009, compared to 75.2% for the ...Rodobo International, Inc. Reports Q2 and First Half of 2009
... decrease of 34% compared to the same period last year. The decrease is mainly attributed to ... 49% compared to 50% in the same period last year. The launch of the "Healthy Elderly" ... was $6.8 million, up 88% compared to the same period last year. The overall gross margin improved from ...PharmAthene Reports First Quarter 2009 Financial and Operational Results
... $5.5 million compared to $5.8 million in the same period of 2008. Revenues for the most recent quarter ... 31, 2009 compared to $5.9 million in the same period last year. For both quarterly periods these ... 31, 2009 compared to $4.4 million in the same period in 2008. These amounts include non-cash stock ...Tiens Biotech Group (USA) Reports First Quarter Results
... or 130.7% over $6.7 million for the same period in 2008, mainly due to greater sales in Indonesia ... a 55.1% decrease from $6.1 million for the same period in 2008. This decrease of domestic revenue was ... of 42% compared to $4.0 million for the same period in 2008. Cost of sales for ...Spectral announces first quarter 2009 results
... compared to $664,000 for the corresponding period in 2008. This represents a 27% increase. Sales in ... compared to $976,000 for the corresponding period in 2009, due to the continued maintenance of a ... or ($0.02) per share for the corresponding period in 2008. Cash and short term investments as at ...Other Contentsplaceboplaceboplaceboplacebopreviapreviapityriasisfasciitisfasciitisplagueplagueplagueplagueplantarplantar
Breaking Biology News(10 mins):New inherited eye disease discovered 2 Killer catfish? Venomous species surprisingly common, study finds 2UCLA researchers engineer bacteria to turn carbon dioxide into liquid fuel 2arGEN X Raises EUR9 5 Million to put SIMPLE Antibody 28TM 29 Platform to Work 13960 1arGEN X Raises EUR9 5 Million to put SIMPLE Antibody 28TM 29 Platform to Work 13960 2arGEN X Raises EUR9 5 Million to put SIMPLE Antibody 28TM 29 Platform to Work 13960 3arGEN X Raises EUR9 5 Million to put SIMPLE Antibody 28TM 29 Platform to Work 13960 4arGEN X Raises EUR9 5 Million to put SIMPLE Antibody 28TM 29 Platform to Work 13960 5WuXi PharmaTech to Participate in Upcoming Investor Conferences 56707 1WuXi PharmaTech to Participate in Upcoming Investor Conferences 56707 2Americas Registered Nurses to Obama 3A 56704 1Americas Registered Nurses to Obama 3A 56704 2
Breaking Medicine News(10 mins):Health News:UNESCO Chair Hosts Jews, Christians, and Muslims in Jerusalem Bioethics Conferences 2Health News:UNESCO Chair Hosts Jews, Christians, and Muslims in Jerusalem Bioethics Conferences 3Health News:UNESCO Chair Hosts Jews, Christians, and Muslims in Jerusalem Bioethics Conferences 4Health News:Early Treatment of Hearing, Vision Helps in Schizophrenia 2Health News:Scientific panel evaluates soy infant formula safety 2
Other TagsConfirmConfirmConfirmConfirmNCINCINCINCINCINCINCIsoarIssueIssueIssueIssueIssueIssuetakendramaticallychipchipchipchipchip[0] UNESCO Chair Hosts Jews, Christians, and Muslims in Jerusalem Bioethics Conferences [0] Genomma Lab Announces Its 2010 Earnings Guidance[0] Medicare Report Confirms Health Care Takeover Plan is a Fiscal Disaster[0] Early Treatment of Hearing, Vision Helps in Schizophrenia[0] Scientific panel evaluates soy infant formula safety
overstatedConfirmNCIclassedsoarSnotIssuetakendramaticallychipminiaturisedcreaturessurprisedexplorers
Other Tagsdelivering 2delivering 3delivering 4delivering 5delivering 6delivering 7delivering 8delivering 9studying 2studying 3studying 4studying 5studying 6studying 7studying 8studying 9studying 10start 2start 3start 4start 5start 6start 7start 8start 9start 10word 2word 3word 4word 5word 6word 7word 8word 9word 10waste 2waste 3waste 4waste 5toxic 2toxic 3toxic 4toxic 5toxic 6toxic 7toxic 8toxic 9toxic 10pollution 2pollution 3pollution 4seizures 2dose 2dose 3dose 4dose 5dose 6dose 7dose 8dose 9| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |